NCT03330847 2026-03-10To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.AstraZenecaPhase 2 Active not recruiting273 enrolled 22 charts
NCT04564027 2025-08-29A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced CancerAstraZenecaPhase 2 Completed54 enrolled 16 charts
NCT02937818 2024-06-07A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerAstraZenecaPhase 2 Completed72 enrolled 29 charts